New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLeuprolide vs Gonadorelin

Leuprolide vs Gonadorelin

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
Leuprolide
Sexual Health & LibidoAnti-Aging & Longevity
Gonadorelin
Summary
Leuprolide is a synthetic GnRH superagonist that, with continuous administration, paradoxically suppresses LH and FSH through receptor desensitization — the opposite effect of pulsatile GnRH. Used medically for prostate cancer, endometriosis, and precocious puberty. In men's health, short-duration use for PCT and testosterone suppression rebound.
Gonadorelin is the synthetic form of endogenous GnRH (gonadotropin-releasing hormone). It stimulates the pituitary to release LH and FSH, maintaining testicular function and testosterone production. Widely used alongside TRT to prevent testicular atrophy and preserve fertility.
Half-Life
~3 hours (SC/IM), but depot formulations last 1–12 months
~2–4 minutes (extremely short); pulsatile dosing required to avoid desensitization
Admin Route
SubQ, IM
SubQ, Intranasal
Research
Typical Dose
7.5 mg monthly, 22.5 mg 3-monthly, or 45 mg 6-monthly
100 mcg
Frequency
Per depot schedule
Twice daily (every 12 hours)
Key Benefits
  • Medical: reduces testosterone in prostate cancer
  • Medical: suppresses estrogen in endometriosis and uterine fibroids
  • Medical: delays precocious puberty
  • Research: testosterone rebound effect after short course
  • Transgender care: hormone suppression in adolescents
  • Research: hormonal re-sensitization protocols
  • Maintains testicular size during TRT
  • Preserves fertility and sperm production during testosterone use
  • Stimulates endogenous LH/FSH production
  • Maintains HPG axis function during exogenous hormone use
  • Used for HCG-free TRT protocols
  • Helps restart natural testosterone production (PCT)
Side Effects
  • Hot flashes (with testosterone suppression)
  • Decreased libido and erectile dysfunction
  • Initial testosterone flare (first 1–2 weeks)
  • Bone density loss with long-term use
  • +3 more
  • Injection site reactions
  • Headache
  • Nausea at initiation
  • Tachycardia (rare)
  • +1 more
Stacks With